Inquiry Basket
Loading ......
Filter By Product Search for
Tilmicosin
Tilmicosin Full Name
Tilmicosin
Tilmicosin Introduction
Tilmicosin is a macrolide antibiotic specifically used in veterinary medicine. It is not a natural product but rather a semi-synthetic derivative obtained through the chemical modification of tylosin. Specifically, it is typically synthesized from desmycosin, a hydrolysis product of tylosin. This structural modification imparts tilmicosin with unique pharmacokinetic properties and enhanced tissue penetration capabilities. As a lipophilic, weakly basic compound, tilmicosin possesses high lipid solubility. This allows it to readily cross cell membranes and achieve and maintain high concentrations in target tissues, particularly the lungs. However, a critically important characteristic of tilmicosin is its significant cardiotoxicity, which constitutes the primary safety risk associated with its use. Accidental injection in humans, even at low doses, can lead to severe cardiovascular reactions and even death.
Figure 1. Schematic illustration demonstrating how tilmicosin, by promoting neutrophil apoptosis, also called programmed cell death (PCD), may generate clinical benefits. (Source: Buret AG. 2010)
As a macrolide antibiotic, the core function of tilmicosin is to exert its antibacterial effect by inhibiting protein synthesis in susceptible microorganisms. Its target is the 50S ribosomal subunit of bacteria. By binding to a specific site on this subunit, tilmicosin effectively blocks the peptide chain elongation process, thereby inhibiting bacterial protein synthesis. At conventional therapeutic concentrations, it primarily exhibits a bacteriostatic effect, though it may also show bactericidal activity against certain pathogens in high-concentration environments, such as within alveolar macrophages. The antibacterial spectrum of tilmicosin is quite broad, primarily covering pathogens that threaten various livestock species. It demonstrates good activity against many Gram-positive bacteria and exerts strong inhibitory effects against key Gram-negative bacteria causing respiratory diseases, such as Mannheimia haemolytica, Pasteurella multocida, and Haemophilus species. Furthermore, it remains effective against mycoplasmas (e.g., Mycoplasma bovis, Mycoplasma gallisepticum), which are often difficult to treat with conventional antibiotics. This targeted spectrum makes it an ideal choice for treating and controlling respiratory complex infections in animals, especially cattle, pigs, sheep, and poultry.
The clinical utility of tilmicosin is largely attributed to its unique pharmacokinetic (PK) profile. Following subcutaneous injection, the drug is rapidly absorbed and widely distributed throughout body tissues. Its high lipophilicity grants it excellent tissue penetration, allowing it to cross cell membranes and accumulate intracellularly, particularly in lung tissue and phagocytic cells like alveolar macrophages and neutrophils. This high concentration at the site of infection is key to its efficacy in treating deep-seated infections like pneumonia. Additionally, tilmicosin has a relatively long half-life in the body, making single-dose administration or dosing at extended intervals feasible. This greatly simplifies treatment protocols and reduces the stress and labor costs associated with frequent animal handling. The drug is ultimately excreted primarily via bile in feces, with a small amount eliminated in urine. These combined pharmacological and pharmacokinetic characteristics define the unique position and value of tilmicosin in veterinary clinical practice, particularly in the field of respiratory disease treatment.
Alternate Names for Tilmicosin
Tilmicosin
Loading ......
